Evaluating Autologous Stromal Vascular Fraction in Subjects with Vocal Fold Scar

Phase 1

Terminated

• Conditions: Vocal Fold Scars
• Interventions: Biological: Autologous adipose derived SVF

• Registration Number: NCT05354544
• Lead Sponsor: Shane A. Shapiro

Brief Summary

The purpose of this research study is to assess if autologous Stromal Vascular Fraction (SVF) taken from the stomach or hips can help heal vocal fold scars.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-08-01
• Study First Submitted: 2022-04-26
• Study First Submitted QC: 2022-04-26
• Study First Posted: 2022-04-29
• Status Verified: 2024-06
• Primary Completion: 2024-12-05
• Study Completion: 2024-12-05
• Last Update Submitted: 2024-12-16
• Last Update Posted: 2024-12-19

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 2

Inclusion Criteria

• Signed informed consent
• Subject's age between 18 and < 80-years-old
• Voice handicap index greater than 10/40
• Scarred vocal folds or congenital sulcus or after vocal fold surgery (Scarring will be scored during examination and identification of scarred vocal folds and hoarseness. This criterion includes the lack of or decreased mucosal wave of the vocal fold during videostroboscopy exam. Scoring of scar based on laryngoscopic exam: Type I: atrophy of lamina propria with/without affected epithelium. Type II: the epithelium, lamina propria, and muscle are affected. Type III: scar located on the anterior commissure. Type IV: this category includes extended scar formation in both anteroposterior and rostro-caudal axis, with significant loss of vocal fold mass)
• Unilateral or Bilateral vocal fold scarring
• At least 1-year delay after initial surgery
• Negative pregnancy test and contraception for woman of childbearing age. Women of childbearing age must use contraception at least 4 months pre and post SVF administration.

Exclusion Criteria

• Refusal of speech therapy

• History of malignant lesion or severe dysplasia of the scarred vocal fold

• Contraindication to anesthesia, anticoagulant treatment, coagulation disorders, active infectious disease

• Refusal or inability to comply with study procedures

• Pregnant and lactating woman

• Major chronic medical condition that could affect treatment or quality of SVF product. These include:

  • Current treatment or within 6 months of last treatment for cancer.
  • Blindness
  • Known history of Dementia,
  • Known history of Kidney Disease
  • Known history of Cerebral Vascular Accident or Stroke

• Known history of Diabetes

• Abnormal screening lab. If the laboratory reports a single, non-clinically relevant, non-life-threatening result for any of these studies and is the only excluding factor it may be repeated 1 week later if the subject wishes. Normalization of that laboratory study will then be considered non-exclusionary.

• Post-Radiation scarring of vocal folds.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
SVF for treating scarred vocal folds	Autologous adipose derived SVF	Subject identified with scarred vocal folds will have autologous adipose derived SVF harvested and applied to scarred vocal folds.

Primary Outcome Measures

Name	Time	Method
Adverse events post SVF administration	24 months	Number of adverse events related to SVF via endoscopy into vocal folds defined as inflammation or swelling indicated by red or swollen vocal folds or evidence of a hemorrhage indicated by a bleed at or near the site of delivery. This will be evaluated during stroboscope exam.

Secondary Outcome Measures

Name	Time	Method
Voice handicap Index	Baseline, Week 1, and Months 1, 3, 6, 9, 12, and 24	Change in the self-reported voice handicap index to describe voices and effects of voices on subject lives, measure using a total score range from 0-120; 0-30=mild, 31-60=moderate, 60-120=severe

Trial Locations

Locations (1)

Mayo Clinic Florida; 🇺🇸 Jacksonville, Florida, United States